Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 1, 2012, Pages 81-92

  Yang, Tingyuan ^a   Wang, Yiguang ^a   Li, Zaiquan ^a   Dai, Wenbing ^a   Yin, Jie ^a   Liang, Liang ^a   Ying, Xue ^a   Zhou, Shufeng ^b   Wang, Jiancheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Combination therapy; Combretastatin A4; Doxorubicin; Targeted delivery; Tumor neovasculature

Indexed keywords

ACTIVE TARGETING; ANTITUMOR EFFECT; ANTIVASCULAR; APOPTOSIS INDUCTION; CANCER MODELS; CELLULAR UPTAKE; COMBINATION THERAPY; COMBINED TREATMENT; COMBRETASTATIN A4; DOXORUBICIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INTEGRINS; LIFE SPAN; LOW DOSE; MICELLE SYSTEMS; NEOVASCULATURE; NOVEL STRATEGIES; RECEPTOR-MEDIATED ENDOCYTOSIS; SOLUTION-CASTING METHOD; TARGETED DELIVERY;

AMINO ACIDS; CELL DEATH; DISEASES; ENDOTHELIAL CELLS; GLYCOLS; GLYCOPROTEINS; LACTIC ACID; LIGANDS; MICELLES; MOLECULAR BIOLOGY; POLYETHYLENE GLYCOLS; TUMORS;

DRUG THERAPY;

COMBRETASTATIN A4; CYCLIC ARGININE GLYCINE ASPARTIC ACID TYROSINE LYSINE PENTAPEPTIDE; DOXORUBICIN; INTEGRIN; MACROGOL; PENTAPEPTIDE; POLYETHYLENE GLYCOL B POLY LACTIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRAIN MCF 7; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIFESPAN; MALE; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; SURFACE CHARGE; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; X RAY POWDER DIFFRACTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LACTATES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICELLES; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; STILBENES;

EID: 84855312255     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.05.003     Document Type: Article

References (49)

1. Hayden E.C. Cutting off cancer's supply lines. Nature 2009, 458:686-687.
2. Tozer G.M., Kanthou C., Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5:423-435.
3. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995, 1:120-122.
4. Folkman J., D'Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 1996, 87:1153-1155.
5. Gillian M.T., Chryso K., Bruce C.B. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5:423-435.
6. Thorpe P.E., Chaplin D.J., Blakey D.C. The first international conference on vascular targeting: meeting overview. Cancer Res 2003, 63:1144-1147.
7. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
8. Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol 2001, 2:733-740.
9. Miller K.D., Sweeney C.J., Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:1195-1206.
10. Fidler I.J., Ellis L.M. Chemotherapeutic drugs-more really is not better. Nat Med 2000, 6:500-502.
11. Zhang L., Yu D., Hicklin D.J., Hannay J.A., Ellis L.M., Pollock R.E. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 2002, 62:2034-2042.
12. Browder T., Butterfield C.E., Kräling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
13. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-24.
14. Verheul H.M., Voest E.E., Schlingemann R.O. Are tumours angiogenesis-dependent?. J Pathol 2004, 202:5-13.
15. Yeung S.C., She M., Yang H., Pan J., Sun L., Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 2007, 92:2902-2909.
16. Siemann D.W., Mercer E., Lepler S., Rojiani A.M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002, 99:1-6.
17. Grosios K., Loadman P.M., Swaine D.J., Pettit G.R., Bibby M.C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000, 20:229-233.
18. Steeg P.S. Angiogenesis inhibitors: motivators of metastasis?. Nat Med 2003, 9:822-823.
19. Dong D., Ko B., Baumeister P., Swenson S., Costa F., Markland F., et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 2005, 65:5785-5791.
20. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
21. Lavasanifar A., Samuel J., Kwon G.S. Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002, 54:169-190.
22. 5 integrins. Bioconjug Chem 2007, 18:1415-1423.
23. Sawant R.R., Torchilin V.P. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 2009, 374:114-118.
24. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003, 100:6039-6044.
25. Seow W.Y., Xue J.M., Yang Y.Y. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. Biomaterials 2007, 28:1730-1740.
26. Pasqualini R., Koivunen E., Ruoslahti E. Peptides in cell adhesion: powerful tools for the study of integrin-ligand interactions. Braz J Med Biol Res 1996, 29:1151-1158.
27. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
28. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
29. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
30. Kim W.J., Yockman J.W., Lee M., Jeong J.H., Kim Y.H., Kim S.W. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release 2005, 106:224-234.
31. Chen X., Plasencia C., Hou Y., Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005, 48:1098-1106.
32. 4 nanoparticles and their specific targeting. J Am Chem Soc 2008, 130:7542-7553.
33. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004, 31:179-189.
34. Smolarczyk R., Cichoń T., Graja K., Hucz J., Sochanik A., Szala S. Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. Acta Biochim Pol 2006, 53:801-805.
35. Zako T., Nagata H., Terada N., Utsumi A., Sakono M., Yohda M., et al. Cyclic RGD peptide-labeled upconversion nanophosphors for tumor cell-targeted imaging. Biochem Biophys Res Commun 2009, 381:54-58.
36. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2756.
37. Yoo H.S., Park T.G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 2001, 70:63-70.
38. Liggins R.T., Burt H.M. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev 2002, 54:191-202.
39. Voigt W. Sulforhodamine B assay and chemosensitivity. Methods Mol Med 2005, 110:39-48.
40. Dubey P.K., Singodia D., Verma R.K., Vyas S.P. RGD modified albumin nanospheres for tumour vasculature targeting. J Pharm Pharmacol 2011, 63:33-40.
41. Xiong X.B., Mahmud A., Uludaǧ H., Lavasanifar A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm Res 2008, 25:2555-2566.
42. Lo C.L., Huang C.K., Lin K.M., Hsiue G.H. Mixed micelles formed from graft and diblock copolymers for application in intracellular drug delivery. Biomaterials 2007, 28:1225-1235.
43. Zelikin A.N., Breheney K., Robert R., Tjipto E., Wark K. Cytotoxicity and internalization of polymer hydrogel capsules by mammalian cells. Biomacromolecules 2010, 11:2123-2129.
44. Yoo H.S., Oh J.E., Lee K.H., Park T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 1999, 16:1114-1118.
45. Grant D.S., Williams T.L., Zahaczewsky M., Dicker A.P. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere). Int J Cancer 2003, 104:121-129.
46. Etrych T., Mrkvan T., Ríhová B., Ulbrich K. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy. J Control Release 2007, 122:31-38.
47. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001, 74:295-302.
48. Tang N., Du G., Wang N., Liu C., Hang H., Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007, 99:1004-1015.
49. Drevs J., Fakler J., Eisele S., Medinger M., Bing G., Esser N., et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24:1759-1763.